mcharltonmd Profile Banner
Michael Charlton MD, FRCP Profile
Michael Charlton MD, FRCP

@mcharltonmd

Followers
1K
Following
338
Media
31
Statuses
205

Director of University of Chicago Transplant Institute. #livertwitter #cirrhosis #liverdisease #NASH #Life. Tweets are my own.

Chicago, IL
Joined May 2016
Don't wanna be here? Send us removal request.
@mcharltonmd
Michael Charlton MD, FRCP
1 year
The ILC at EASL winds down. Best ever. This was our Last Supper.
Tweet media one
10
7
72
@mcharltonmd
Michael Charlton MD, FRCP
1 year
New fave pic. On the L is Stefano Romeo, 1st author on PNPLA3 in MASLD Nature paper. On the R is Greg Tesz, lead scientist at Pfizer for first PNPLA3 Rx in human studies. From genetic assn to clinical trial. I ❤️ it! Keystone Symposia are a lot of work. But worth it! 💪 2gether.
Tweet media one
1
1
19
@mcharltonmd
Michael Charlton MD, FRCP
1 year
Some early Keystone insights: Weight loss is less of a driver of MASLD histology than we thought. FFA are the major source of hepatic lipids (not DNL) and we are what our parents ate, at least epigenetically. 🤔
Tweet media one
0
0
8
@mcharltonmd
Michael Charlton MD, FRCP
1 year
Keystone MASH and Fibrosis: Molecular Phenotypes to Precision Therapeutics has kicked off with Arun Sanyal delivering the Keynote opener. A masterful synthesis of a doyen’s knowledge!
Tweet media one
2
3
14
@mcharltonmd
Michael Charlton MD, FRCP
2 years
RT @gnioannou: In this meta-analysis of individual patient data, liver biopsy performed the same as FIB-4, fibroscan liver stiffness and NA….
0
29
0
@mcharltonmd
Michael Charlton MD, FRCP
2 years
RT @JVLazarus: @ebtapper The #MASLDnomenclature article in @HEP_Journal is now ranked 16th of >8500 articles tracke….
0
8
0
@mcharltonmd
Michael Charlton MD, FRCP
2 years
RT @BBCMorningLive: Over 10,000 lives are lost to liver disease in the UK each year. On Monday’s show, Dr @xandvt joins us to talk about th….
0
6
0
@mcharltonmd
Michael Charlton MD, FRCP
2 years
Some thoughts on the first in person EASL / ILC meeting since pandemic:.👉Attendance for major meetings (AASLD, EASL) ~60% of peak pre-COVID. Will be $$ challenges. 👉In person far superior to Zoom etc. 👉Liver science is accelerating (NASH, HCC and HBV on 🔥).👉🙏🏻👏 #EASL
Tweet media one
1
0
23
@mcharltonmd
Michael Charlton MD, FRCP
2 years
RT @orenkfix: When is the last time this many organizations agreed on something? This is an impressive turnout in support of the new nomenc….
0
12
0
@mcharltonmd
Michael Charlton MD, FRCP
2 years
Tweet media one
1
3
55
@mcharltonmd
Michael Charlton MD, FRCP
2 years
RT @AASLDtweets: It’s true! #NAFLDNomenclature is now known as #MASLDNomenclature. MASLD (pronunciation: Ma-zuld) encompasses patients who….
0
76
0
@mcharltonmd
Michael Charlton MD, FRCP
2 years
The guard has changed. Thank you and farewell NAFLD, NASH and MAFLD. Welcome SLD, MASLD and MASH! Well done and thank you to the Delphi panel and the 60+ medical societies who have already endorsed. @AASLDtweets @EASLnews @marurinella @phil_newsome7 @GlobalLiver @LiverSaver
Tweet media one
Tweet media two
Tweet media three
0
18
40
@mcharltonmd
Michael Charlton MD, FRCP
2 years
With OCA a new casualty of a palpably capricious FDA review process, not only is an effective agent lost and the field chilled but the costs of unscientific adcom decisions will be baked into Rx costs. FDA review shouldn’t resemble a ride in the Titan sub. #LiverTwitter #FDA.
0
1
0
@mcharltonmd
Michael Charlton MD, FRCP
2 years
Mine too!.
@MeenaBBansal
Meena Bansal
2 years
My favorite family @ddw2023@AASLDtweets#livertwitter@DrLoomba⁩ ⁦@NoureddinMD⁩ ⁦@marurinella⁩ ⁦⁦@mcharltonmd⁩ ⁦@DOMSinaiNYC
Tweet media one
1
1
13
@mcharltonmd
Michael Charlton MD, FRCP
2 years
Important topic + great investigators and speakers = Think differently by the conclusion of the conference. See you there!! Banff quite a nice place too.
@stefano_romeo76
Stefano Romeo
2 years
Interested in NASH and precision therapeutics? I look forward to seeing you all at the 2024 Keystone on NASH and fibrosis in Banff!
Tweet media one
0
0
6
@mcharltonmd
Michael Charlton MD, FRCP
2 years
These are a great way to stay current with the most exciting new publications in our field - highly recommend!.
0
3
6
@mcharltonmd
Michael Charlton MD, FRCP
3 years
It’s here. And it is wonderful: AASLD practice guidance on nonalcoholic fatty liver disease - PubMed. Well done!! And kudos to the first author, our very own Maru Rinella!! 🍾👏 ⁦@UChicagoGI⁩ ⁦@marurinella#livertwitter ⁦⁦@DrLoomba
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
3
5
38
@mcharltonmd
Michael Charlton MD, FRCP
3 years
RT @SanjayaSatapath: INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD @AASLDtweets @INASL_Liver @APAS….
0
6
0
@mcharltonmd
Michael Charlton MD, FRCP
3 years
Well done Ray and team! An overdue and important tinker!!.
@WRayKimMD
W Ray Kim
3 years
I am going to commit the ‘sin’ of over-communicating this one. ➡️MELD3.0 will soon replace the current version of MELD. More work to be done - some will be presented at #TLM2022, where we have 3 podium presentations. @AASLDtweets @allisonkwong .
0
0
4